Does nebivolol influence serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats?

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 86-94

  Górska, Dorota ^a   Dudarewicz, Michał ^a   Czarnecka, Elzbieta ^a   Andrzejczak, Dariusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

LPS; Nebivolol; Proinflammatory cytokines; SHR; WKY

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEBIVOLOL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HYPERTENSION; IMMUNOMODULATION; IN VIVO STUDY; LIPID ANALYSIS; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 77950833511     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70245-0     Document Type: Article

References (37)

1. Agabiti Rosei E, Rizzoni D: Metabolic profile of nebivolol, a β-adrenoceptor antagonist with unique characteristics. Drugs, 2007, 67, 1097-1107.
2. Andrzejczak D, Górska D, Czarnecka E: Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1β, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep, 2006,58,711-719.
3. Andrzejczak D, Górska, D, Czarnecka E: Influence of hypotensive drugs on lipopolysaccharide (LPS)-induced serum concentrations of tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep, 2007, Suppl 1, 59,183-191.
4. Bautista LE, Vera LM, Arenas IA, Gamarra G: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens, 2005, 19, 149-154.
5. Bhagat K, Vallance P: Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation, 1997, 96, 3042-3047.
6. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC: Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med, 1997, 129, 300-308.
7. de Nigris F, Mancini FP, Balestrieri ML, Byrns R, Fiorito C, Williams-Ignarro S, Palagiano A et al.: Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide, 2008, 19, 57-63.
8. Dredge K, Connor TJ, Kelly JP, Leonard BE: Differen-tial effect of a single high dose of the tricyclic antide-pressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysac-charide challenge in rats. Int J Immunopharmacol, 1999, 21,663-673.
9. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA et al.: Endo-toxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate he-patic triglyceride production while high doses inhibit clearance. J Lipid Res, 1992, 33, 1765-1776.
10. Gandhi C, Zalawadia R, Balaraman R: Nebivolol re-duces experimentally induced warm renal ischemia reperfusion injury in rats. Ren Fail, 2008, 30, 921-930.
11. Garbin U, Fratta Pasini A, Stranieri C, Manfro S, Mozzini C, Boccioletti V, Pasini A et al.: Effects of ne-bivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm, 2008, 2008, 367-590.
12. Górska D, Andrzejczak D: Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats. Pol J Pharmacol, 2003, 55, 409-417.
13. Guerrero E, Voces F, Ardanaz N, Montero MJ, Arévalo M, Sevilla MA: Long-term treatment with nebivolol im-proves arterial reactivity and reduces ventricular hyper-trophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol, 2003, 42, 348-355.
14. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ: Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens, 2006, 24, 151-158.
15. Ignarro LJ: Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Cardio-vasc Ther, 2008, 26, 115-134.
16. Ignarro LJ: Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl, 2004, 1, 2-16.
17. Krone W, Nägele H: Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J, 1988, 116, 1729-1734.
18. Kuroedov A, Cosentino F, Lüscher TF: Pharmacological mechanisms of clinically favorable properties of a selec-tive -adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev, 2004, 22, 155-168.
19. Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch W et al.: Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase acti-vation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol, 2006, 33, 720-724.
20. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T: Effect of nebivolol on endothelial nitric ox-ide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol, 2006,48,862-869.
21. Mauno V, Hannu K, Esko K: Proinflammation and hypertension: a population-based study. Mediators Inflamm, 2008,2008,619-704.
22. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, Wendt M et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol, 2003, 23, 615-621.
23. Pastelín Hernández G, Rosas Peralta M. Inflammation in high blood pressure. Arch Cardiol Mex, 2007, Suppl 4, 77, S4-172-S4-174.
24. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE: The receptor binding profile of the new anti hypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol, 1988, 34, 843-851.
25. Peter P, Martin U, Sharma A, Dunne F: Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther, 2006, 31, 153-159.
26. Renna N, Risler N, Cruzado M, Gonzalez S, Lama C, Miatello RM: Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance. Cell Mol Biol (Noisy-le-Grand), 2005, 51, 531-537.
27. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther, 2003, 8, 127-134.
28. Savoia C, Schiffrin EL: Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond), 2007, 112, 375-384.
29. Schmidt AC, Flick B, Jahn E, Bramlage P: Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers. Vasc Health Risk Manag, 2008, 4, 909-915.
30. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol, 1988, 11, 552-563.
31. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI: Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens, 1997, 11, 813-819.
32. Veverka A, Nuzum DS, Jolly JL: Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother, 2006,40,1353-1360.
33. Wagenfeld L, Himpel O, Galambos P, Matthiesen N, Wiermann A, Richard G, Klemm M et al.: Protective effects of nebivolol on oxygen free radical-induced vasoconstrictionsinvitro.Med Sci Moni, 2008, 14, BR109-BR112.
34. Wolf SC, Sauter G, Jobst J, Kempf VA, Risler T, Brehm BR: Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol, 2008, 125, 4-10.
35. Wolf SC, Sauter G, Preyer M, Poerner T, Kempf VA, Risler T, Brehm BR: Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem, 2007, 19, 129-136.
36. Zeitz O, Galambos P, Matthiesen N, Wagenfeld L, Schillinger W, Wiermann A, Richard G et al.: Effects of the systemic beta-adrenoceptor antagonist nebivolol on ocular hemodynamics in glaucoma patients. Med Sci Monit, 2008, 14, CR268-CR275.
37. Zhang C: The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol, 2008, 103, 398-406.